ACAM2000 Smallpox Vaccine Description
ACAM2000 is a live vaccinia virus, a replication-competent vaccine, to protect against smallpox disease. The vaccine does not contain the variola virus and cannot cause smallpox. However, It contains the vaccinia virus, which belongs to the poxvirus family, genus Orthopoxvirus.
Replication-competent smallpox vaccine consists of a live, infectious vaccinia virus that can be transmitted from the vaccine recipient to unvaccinated persons who have close contact with the inoculation site or with exudate from the site.
ACAM2000 is licensed in the U.S. by the Food and Drug Administration, and it was developed under a contract with the U.S. Centers for Disease Control and Prevention (CDC).
The vaccinia virus may cause rash, fever, and head and body aches.
ACAM2000 vaccine is the primary smallpox vaccine designated for use in a bioterrorism emergency and forms the majority of the U.S. Government's smallpox vaccine stockpile. More than 200 million doses of ACAM2000 have been supplied to the US Government for its Strategic National Stockpile and has also been supplied under an FDA Investigational New Drug application to several other governments worldwide.
Gaithersburg, Maryland-based Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life.
ACAM2000 Smallpox Vaccine Indication
ACAM2000 is indicated for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection.
Smallpox vaccines are no longer routine, although some soldiers and laboratory workers still are inoculated.
ACAM2000 Smallpox Vaccine Dosage
ACAM2000 is administered as a single dose by the percutaneous route using the multiple punctures technique.
The risk of side effects in household contacts is the same as those for the vaccine recipient. Therefore, the vaccination site requires special care to prevent the virus from spreading.
ACAM2000 Smallpox Vaccine News
September 3, 2019 - Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000 Into the Strategic National Stockpile. Robert G. Kramer Sr., president and chief executive officer of Emergent BioSolutions, stated, "Emergent applauds the U.S. government’s continued focus on national security demonstrated through its long-term stockpiling strategy, which ensures a sustainable supply of critical medical countermeasures such as ACAM2000 vaccine, and its investment in a stable domestic manufacturing infrastructure to help protect the U.S. population against smallpox in the event of an attack."
June 21, 2019 - Emergent BioSolutions Completes Acquisition of ACAM2000® Business From Sanofi.
February 19, 2021 - Emergent reported fourth-quarter 2020 earnings of $3.67 per share, improving from the year-ago quarter’s earnings of $1.57.
ACAM2000 Smallpox Vaccine Clinical Trials
Clinical Trial NCT00053482: Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults
Clinical Trial NCT01158157: VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV
Clinical Trial NCT02443623: VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV